Skip to main content
Back
Watch Compare

COGNITION THERAPEUTICS INC

Data quality: 83%
CGTX
NASDAQ Manufacturing Chemicals
$0.91
▲ $0.04 (5.21%)
Mkt Cap: 77.42 M
Price
$0.87
Mkt Cap
77.42 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -24.59 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-107.84%
Below sector avg (-54.01%)
ROIC-171.65%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio6.44
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-3.30 | -3.02
Below sector avg (-1.49)
P/B Ratio2.12
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -3.3 -1.5
P/B 2.1 1.6
ROE % -107.8 -54.0
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

4 analysts
Buy
Current
$0.91
+286.7%
Target
$3.50
$3.00
$3.50
$4.00
Forecast
Forward P/E -3.02
Forward EPS -$0.30
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.30
-$0.50 – -$0.19
 0.0 3
FY2026 -$0.32
-$0.46 – -$0.14
 0.0 4

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.08 -$0.02 +74.2%
Q32025 -$0.09 -$0.06 +33.3%
Q22025 -$0.11 -$0.11 -4.8%
Q12025 -$0.12 -$0.14 -21.7%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -23.49 M
ROE -107.84% ROA -74.54%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -24.59 M
ROIC -171.65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6.44
Interest Coverage N/A Asset Turnover N/A
Working Capital 36.23 M Tangible Book Value 36.53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.30 Forward P/E -3.02
P/B Ratio 2.12 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -31.77%
Market Cap 77.42 M Enterprise Value 38.08 M
Per Share
EPS (Diluted TTM) -0.32 Revenue / Share N/A
FCF / Share -0.28 OCF / Share -0.28
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 104.70%
SBC-Adj. FCF -27.22 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -23.49 M -33.97 M -25.79 M -21.40 M -11.72 M
EPS (Diluted) -0.32 -0.86 -0.86 -0.91 -3.13
Gross Profit — — — — —
Operating Income -47.80 M -53.97 M -50.72 M -43.55 M -28.60 M
EBITDA — — — — —
R&D Expenses 37.19 M 41.68 M 37.20 M 30.32 M 18.57 M
SG&A Expenses — — — — —
D&A 36,000.0 107,000.0 96,000.0 83,000.0 93,000.0
Interest Expense — — -27,000.0 -28,000.0 895,000.0
Income Tax 0.0 0.0 0.0 0.0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 48.39 M 30.23 M 35.16 M 50.43 M 59.14 M
Total Liabilities 14.12 M 11.48 M 10.69 M 10.18 M 7.86 M
Shareholders' Equity 34.27 M 18.75 M 24.47 M 40.25 M 51.27 M
Total Debt — — — — —
Cash & Equivalents 36.81 M 25.01 M 29.92 M 41.56 M 54.72 M
Current Assets 47.99 M 29.56 M 34.22 M 47.65 M 58.99 M
Current Liabilities 13.92 M 11.14 M 10.17 M 7.80 M 7.86 M